EcoDrugPlus

Eph Receptor B4

Ensembl ID : ENSVVUG00000023535
Gene Symbol: EPHB4
3 Cross references
166 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSVVUG00000016472
Gene Symbol: F2RL3
2 Cross references
197 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSVVUG00000027395
Gene Symbol: FAU
3 Cross references
251 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSVVUG00000006695
Gene Symbol: FYN
3 Cross references
261 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSVVUG00000009055
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSVVUG00000024387
Gene Symbol: GPR84
3 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSVVUG00000008592
Gene Symbol: HCK
3 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSVVUG00000004409
Gene Symbol: ITK
3 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSVVUG00000013996
Gene Symbol: JAK1
3 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSVVUG00000007315
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSVVUG00000010219
Gene Symbol: JAK3
3 Cross references
103 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSVVUG00000030345
Gene Symbol: KRAS
2 Cross references
203 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).